USFDA completes inspection of Cadila with zero observations

USFDA completes inspection of Cadila with zero observations, the facility is situated at Baddi

Picture: Pixabay

Cadila Healthcare Ltd announced that US Food and Drug Administration (FDA) issued Form 483 with zero observations to the company’s Baddi unit.

“US FDA inspected the company’s formulations manufacturing facility located at Baddi from March 2 to March 9, 2020. This was a cGMP and post approval inspection, the company said in a BSE filing.

Also read : Natco Pharma completes USFDA inspection

Cadila Healthcare Ltd is an Indian pharmaceutical company headquartered at Ahmedabad in Gujarat state of western India. The company is one of the leading pharmaceutical companies in India.

It is a manufacturer of generic drugs. The company makes active pharmaceutical ingredients at three sites in India, Ankleshwar plants, Vadodara plant, and Patalganga plant.